SS-31 (Elamipretide)
1000 mcg · Mon-Fri (5x/week)
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 2 cited sources
Evidence
- Human Studies
- 10
- Animal Studies
- 80
- Clinical Status
- Investigational
- Confidence
- Moderate
- Long-Term Safety
- Moderate for the specific rare-disease populations studied in trials; general anti-aging use is not what was studied
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane and is studied for stabilizing mitochondrial structure and reducing oxidative stress. It has been through pharmaceutical clinical trials (as elamipretide) for specific mitochondrial diseases.
Common Protocols
- 1000 mcg 5x/week, subcutaneous
- Clinical trials for specific conditions used daily subcutaneous dosing
Side Effects
- Injection site reactions were the most common finding in clinical trials
- General-population, off-label use is far less studied than the trial populations
Interactions
- No well-characterized interactions; formal data limited to trial populations
Practical Details
- Cost
- $$$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Karaa A et al. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 trial. Neurology. PMID 37268435.
- Reid Thompson W et al. (2021). A phase 2/3 randomized clinical trial of elamipretide in Barth syndrome. Genet Med. PMID 33077895.
Search the Research
SS-31 (Elamipretide) FAQ
What is the typical SS-31 (Elamipretide) dosage?
Commonly reported protocols: 1000 mcg 5x/week, subcutaneous; Clinical trials for specific conditions used daily subcutaneous dosing. Our reference entry uses 1000 mcg, Mon-Fri (5x/week). These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of SS-31 (Elamipretide)?
Reported side effects include: Injection site reactions were the most common finding in clinical trials; General-population, off-label use is far less studied than the trial populations.
Is SS-31 (Elamipretide) FDA approved?
SS-31 (Elamipretide) is still being studied in clinical trials and is not FDA approved. Products sold outside those trials are not the same as a regulated drug.
How much research is there on SS-31 (Elamipretide)?
Our evidence profile counts roughly 10 human and 80 animal studies, with moderate overall confidence. Long-term safety: Moderate for the specific rare-disease populations studied in trials; general anti-aging use is not what was studied.
Does SS-31 (Elamipretide) interact with other drugs or supplements?
No well-characterized interactions; formal data limited to trial populations.
How do I reconstitute SS-31 (Elamipretide)?
A common setup is a 10 mg vial mixed with 2 mL of bacteriostatic water, which puts a 1000 mcg dose at about 20 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
No known interactions with rest of protocol